Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors MM-151 is Merrimack's fifth program to enter clinical development
CAMBRIDGE, Mass., Jan. 11, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
The Phase 1 study will assess the safety of MM-151 and determine the recommended Phase 2 dose. Four sites are currently expected to participate in this trial. The first patient was enrolled at the Indiana University Health Arnett and Horizon Oncology clinical site.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.
Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, firstname.lastname@example.org
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, email@example.com
SOURCE Merrimack Pharmaceuticals, Inc.